Reading Time: 2 minutesIntroduction Noonan Syndrome, a genetic disorder characterized by distinctive facial features, congenital heart defects, and short stature, poses significant challenges to affected individuals, particularly in terms of growth and overall health. In the United States, where the prevalence of Noonan Syndrome is estimated to be around 1 in 1,000 to 1 in 2,500 live births, the quest for effective treatments remains a critical focus for medical research. Saizen, a recombinant human growth hormone, has emerged as a promising therapeutic option. This article delves into a longitudinal study spanning ten years, assessing the efficacy of Saizen in improving growth and health … Read more »